Analyst Research

Report Title Price
Provider: Reuters Investment Profile
Provider: Wright Reports
Provider: GlobalData
Provider: GlobalData

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

PledPharma announces positive data from first part of PLIANT study

Wednesday, 12 Feb 2014 02:30am EST 

PledPharma publ AB:Says the results from the first part of the PLIANT study show that PledOx was well tolerated by patients treated with FOLFOX chemotherapy.Says such side effects as neuropathies did not occur in patients who were pre-treated with PledOx.Says the lower dose of PledOx also indicated a reduction of serious white blood cell-related side effects. 

Company Quote

-0.5 -2.79%
20 Oct 2014